Health Canada Approves Lilly’s Mounjaro to Reduce Cardiovascular Risk
Health Canada approved Lilly’s Mounjaro (tirzepatide) for reducing cardiovascular risk in adults with type 2 diabetes.
Health Canada approved Lilly’s Mounjaro (tirzepatide) for reducing cardiovascular risk in adults with type 2 diabetes.